Alexion Pharmaceuticals, Inc.

Portola Pharmaceuticals, Inc.

Srx Cardio, LLC

Mark Karbarz

Genmin Lu

Pamela B Conley

Anjali Pandey

Thomas E Barta

Uma Sinha

Simeon Bowers

Jonathan William Bourne

Jiang Zhu

The present disclosure relates to novel compounds capable of binding to PCSK9, thereby modulating PCSK9 biological activity. Also provided are compositions comprising these compounds, methods of preparing the compounds, and methods for use of the compounds in the treatment of PCSK9-related conditions and diseases.

Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)

The present disclosure provides methods for manufacturing a fXa derivative protein at large scale leading to high yield of highly pure protein product. The method may include adding a detergent to a sample that contains a polynucleotide construct encoding the protein and purifying the protein through a soybean trypsin inhibitor (STI)-based affinity chromatograph, an ion exchange and mixed mode chromatograph and a hydrophobic interaction.

Preparation of factor Xa derivatives

Growing community of inventors

South San Francisco, CA, United States of America

Mark Karbarz